Order results by:
Issue | Title | |
Vol 11, No 4 (2019) | Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects» | Abstract similar documents |
N. V. Khachanova, A. N. Boyko, K. Z. Bakhtiyarova, Ya. V. Vlasov, E. P. Evdoshenko, S. A. Sivertseva, T. E. Schmidt, M. V. Shumilina | ||
"... with both persistent disease activity (SPMS with exacerbations) and disability progression without ..." | ||
Vol 11, No 4 (2019) | New possibilities for the therapy of secondary progressive multiple sclerosis | Abstract similar documents |
A. M. Petrov, E. V. Ivashkova, I. D. Stolyarov | ||
"... in slowing the progression of disability in patients with SPMS in the international phase III (EXPAND ..." | ||
Vol 13, No 6 (2021) | Changes in retinal structures as markers of multiple sclerosis progression | Abstract similar documents |
M. O. Poplyak, A. G. Trufanov, A. V. Temniy, D. S. Maltsev, O. B. Chakchir, A. V. Mikheev, D. I. Skulyabin, G. N. Bisaga, I. V. Litvinenko, M. M. Odinak | ||
"... activity in patients with RMS and assessment of its progression in patients with SPMS. ..." | ||
Vol 15 (2023): (Suppl. 1) | MicroRNAs as biomarkers of multiple sclerosis progression | Abstract similar documents |
N. M. Baulina, I. S. Kiselev, O. G. Kulakova, E. V. Popova, O. O. Favorova, A. N. Boyko | ||
"... progressive MS (PPMS and SPMS, respectively). Currently, there is an active search for MS biomarkers capable ..." | ||
Vol 16 (2024): (Suppl. 2) | Optimization of therapy in secondary progressive multiple sclerosis | Abstract similar documents |
A. N. Boyko, S. K. Zyryanov, Ya. V. Vlasov | ||
"... sclerosis (SPMS). The only drug that has proven its effectiveness in all types of SPMS (with exacerbations ..." | ||
Vol 12, No 1 (2020) | Association of BAFF gene polymorphisms with multiple sclerosis progression | Abstract PDF (Eng) similar documents |
I. V. Smagina, S. A. Elchaninova, A. S. Palashchenko | ||
"... 1224141, rs9514827) with the progression rate and frequency of MS exacerbations. Patients and methods ..." | ||
Vol 4, No 2 (2012) | Clinical characteristics of multiple sclerosis in the Tomsk region | Abstract similar documents |
V M Alifirova, M A Titova | ||
"... moderate neurologic deficit and moderate disease progression. The women were observed to exhibit a more ..." | ||
Vol 16, No 5 (2024) | Efficacy and safety of cladribine tablets in multiple sclerosis in real-world clinical practice | Abstract similar documents |
A. N. Peshkin, S. V. Kotov, G. T. Toniya, M. V. Sutormin, A. F. Eltayoury | ||
"... -life clinical practice in MS patients with frequent exacerbations and rapid disability progression ..." | ||
Vol 11, No 1 (2019) | Experience with anti-B-cell therapy in the pathogenetic treatment of multiple sclerosis | Abstract PDF (Eng) similar documents |
O. V. Boyko, S. V. Petrov, N. Yu. Lashch, M. R. Guseva, A. N. Boyko | ||
"... MS (PPMS), secondary progressive MS (SPMS) and exacerbations, and highly active MS. Objective ..." | ||
Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Comparison of medical and social characteristics and quality of life of patients with primary- and secondary-progressive multiple sclerosis | Abstract similar documents |
Ya. V. Vlasov, N. G. Polyarnaya, A. N. Boyko | ||
"... Management of patients with secondary progressive multiple sclerosis (SPMS) remains one ..." | ||
Vol 6, No 3 (2014) | Visual evoked potentials in examining the visual analyzer in patients with multiple sclerosis | Abstract similar documents |
S. M. Karpov, Z. B. Pazhigova, E. N. Karpova | ||
"... MS (RRMS), 9.1±4.2 years in secondary progressive MS (SPMS), and 2.7±1.9 years in primary progressive ..." | ||
Vol 13, No 1 (2021) | The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’ | Abstract similar documents |
V. V. Kovalchuk | ||
Vol 9, No 2 (2017) | Chronic cerebral ischemia, neuroplasticity, possibilities of therapy | Abstract similar documents |
E. I. Chukanova, A. S. Chukanova | ||
"... , progression, and risk of exacerbations in patients with chronic cerebral ischemia. ..." | ||
Vol 14, No 5 (2022) | Current view on the diagnosis and treatment of neuromyelitis optica spectrum disorders exacerbations | Abstract similar documents |
V. S. Krasnov, L. N. Prakhova, N. A. Totolyan | ||
"... ) are formed as a result of exacerbations, which are often life-threatening. Timely diagnosis and treatment ..." | ||
Vol 15 (2023): (Suppl. 1) | Prolonged observation after the use of cladribine in multiple sclerosis: efficacy and safety | Abstract similar documents |
A. D. Kukushkina, A. N. Boyko | ||
"... neuroinflammatory and neurodegenerative components. The goal of therapy of MS is to reduce the risk of exacerbations ..." | ||
Vol 13, No 1 (2021) | New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis | Abstract similar documents |
D. S. Kasatkin, N. V. Khachanova, V. M. Alifirova, A. N. Boyko, K. Z. Bakhtiyarova, Ya. V. Vlasov, M. V. Davydovskaya, E. P. Evdoshenko, S. A. Sivertseva | ||
"... during the transition to secondary progression. This paper reflects the opinion of the Council of Leading ..." | ||
Vol 1, No 2 (2009) | METABOLIC CORRECTION OF NEUROLOGICAL COMPLICATIONS OF DIABETES MELLITUS | Abstract similar documents |
S. A. Rumyantseva, V. A. Stupin, E. V. Silina, V. V. Mikhal'skiy, A. I. Perevedentsev, D. D. Ryzhova | ||
"... and progression of neurological complications of diabetes mellitus are presented. The results of some ..." | ||
Vol 14, No 6 (2022) | Alzheimer's disease and COVID-19 | Abstract similar documents |
N. N. Koberskaya, F. A. Roshchin | ||
"... to the accumulation of beta-amyloid and the subsequent onset or progression of current AD. The involvement ..." | ||
Vol 4, No 2 (2012) | A change in the parameters of P300 evoked potentials in relation to the degree of exacerbation of pain syndrome | Abstract similar documents |
A P Rachin, A A Averchenkova | ||
Vol 17, No 1 (2025) | Aggressive multiple sclerosis in the Republic of Bashkortostan | Abstract similar documents |
K. Z. Bakhtiyarova, U. Sh. Kuzmina, O. V. Lyutov, I. D. Talipova, N. F. Akhmetgaleeva, T. R. Galiullin, M. A. Kutlubaev | ||
"... Treatment of patients with aggressive multiple sclerosis (MS) characterized by severe progression ..." | ||
Vol 11, No 2 (2019) | Vascular factors in the genesis of dementia and the optimization of patient management | Abstract similar documents |
O. D. Ostroumova, A. I. Kochetkov | ||
"... at monitoring vascular risk factors, preventing stroke and progression of chronic cerebrovascular disease ..." | ||
Vol 11, No 2 (2019) | Pathogenesis, clinical features, and treatments of depression in Parkinson's disease | Abstract similar documents |
I. V. Milyukhina | ||
"... significantly affects the rate of disease progression and increases the risk of motor complications and dementia ..." | ||
Vol 16, No 6 (2024) | Management of patients with cognitive impairment in old age | Abstract similar documents |
D. A. Grishina, A. B. Lokshina, E. A. Sokolov | ||
"... progression. The possibilities of modern neuroprotective and symptomatic therapy of MCI and the role ..." | ||
Vol 13, No 5 (2021) | Treatment of cognitive impairment in arterial hypertension | Abstract similar documents |
Yu. A. Starchina, K. S. Sleptcova | ||
"... therapy plays an essential role in preventing the development and slowing the progression of CI ..." | ||
Vol 10, No 3 (2018) | Benign syringomyelia with the abortive type of the course | Abstract PDF (Eng) similar documents |
E. G. Mendelevich, Ch. S. Nurullina | ||
"... , lack of progression and/or development of myelopathic symptoms, and signs of syringomyelia cavity ..." | ||
Vol 11, No 3S (2019): Спецвыпуск: когнитивные нарушения, цереброваскулярные заболевания | Vascular depression and cognitive dysfunction | Abstract similar documents |
A. N. Bogolepova | ||
"... , also has a negative impact on the course of cardiovascular disease, contributing to its progression ..." | ||
Vol 8, No 3 (2016) | Amyotrophic lateral sclerosis with extension of the central canal of the spinal cord according to magnetic resonance imaging data | Abstract similar documents |
E. G. Mendelevich, G. R. Mukhamedzhanova, E. I. Bogdanov | ||
"... are atypical for ALS, such as early age of onset, slow progression with long-term involvement of one leg ..." | ||
Vol 1, No 3-4 (2009) | COMPLEX THERAPY FOR HYPERTENSIVE AND MIXED ENCEPHALOPATHY | Abstract similar documents |
S. A. Rumyantseva | ||
"... Arterial hypertension (AH) is one of the main causes of the occurrence and progression of different ..." | ||
Vol 5, No 4 (2013) | Cognitive impairments in epilepsy | Abstract similar documents |
Aleksandr Anatolyevich Kostylev, N V Pizova, N A Pizov | ||
"... the detection of new features in the course and progression of higher nervous system dysfunctions in epilepsy. ..." | ||
Vol 4, No 2 (2012) | Artra is a model of combination symptom-modifying therapy for osteoarthrosis and intervertebral osteochondrosis | Abstract similar documents |
V V Badokin | ||
"... , but also to the slow progression, normalization, or stabilization of structural changes in the hyaline ..." | ||
Vol 11, No 4 (2019) | Poststroke cognitive impairment | Abstract similar documents |
V. A. Parfenov | ||
"... the progression of CI in stroke patients. The use of Actovegin in patients with CI after stroke is discussed ..." | ||
Vol 9, No 2 (2017) | Cognitive impairment without dementia: A current view of the problem | Abstract similar documents |
Yu. A. Starchina | ||
"... allows the progression of CI to be curbed. The paper discusses the use of EGB761® in patients with CI. ..." | ||
Vol 17, No 1 (2025) | Contribution of genomic variation to the severity of multiple sclerosis | Abstract similar documents |
O. G. Kulakova, N. A. Matveeva, I. S. Kiselev, A. N. Boyko, O. O. Favorova | ||
"... the genetic basis of MS progression may not only explain the nature of the observed clinical heterogeneity ..." | ||
Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Influence of von Willebrand factor on common pathophysiological mechanisms of cerebrovascular diseases and multiple sclerosis | Abstract similar documents |
I. A. Koltsov, M. Yu. Martynov, A. N. Yasamanova, I. A. Shchukin, M. S. Fidler, A. N. Boyko | ||
"... to the development/progression of many diseases, including cerebrovascular disease and multiple sclerosis. Von ..." | ||
Vol 13, No 5 (2021) | Paradoxial embolism as a cause of ischemic stroke in patient with sinus venosus atrial septal defect | Abstract PDF (Eng) similar documents |
A. A. Kulesh, S. A. Mekhryakov, L. I. Syromyatnikova, N. H. Gorst, S. O. Drobakha, E. V. Nikolaeva | ||
"... cerebral accidents and the progression of pulmonary hypertension, and the prevention of the development ..." | ||
Vol 14, No 4 (2022) | Cognitive impairment in patients with coronavirus infection | Abstract similar documents |
Y. A. Starchina, O. V. Kosivtsova | ||
"... the clinical onset and progression of CI, including Alzheimer's disease. For the treatment of severe CI after ..." | ||
Vol 13, No 1 (2021) | Chronic cerebral ischemia and headache in patients in primary care physician's practice | Abstract similar documents |
V. N. Shishkova, T. V. Adasheva | ||
"... of effective treatment, prevents the disease progression, and the development of strokes and dementia ..." | ||
Vol 11, No 2S (2019): Спецвыпуск: боль в спине и конечностях | Facet joint osteoarthritis as a component of non-specific low back pain | Abstract similar documents |
O. S. Davydov | ||
"... complete pain relief in most cases and slows the progression of the disease. ..." | ||
Vol 11, No 3 (2019) | Vascular cognitive impairment and Alzheimer's disease: Is there a relationship between them? | Abstract similar documents |
G. R. Tabeeva, E. A. Kirjanova | ||
"... on the clinical manifestation, severity, and rate of progression of CI. Alzheimer's disease (AD) and vascular CI ..." | ||
Vol 9, No 4 (2017) | Hypertension and cognitive impairment: the standpoint of evidence-based medicine | Abstract similar documents |
T. M. Ostroumova, V. A. Parfenov, O. D. Ostroumova | ||
"... cognitive function and prevents the progression of CI and the development of dementia. The use ..." | ||
Vol 2, No 4 (2010) | Smoking and ischemic stroke | Abstract similar documents |
D. V. Neverovskiy | ||
"... . Smoking contributes to the progression of atherosclerosis, the elevation of blood pressure ..." | ||
Vol 15, No 4 (2023) | The role of trimethylamine-N-oxide in the development of cerebrovascular disease (brief review) | Abstract similar documents |
M. A. Kutlubaev, A. R. Rakhmatullin, R. F. Kutlubaeva | ||
"... to the acceleration of atherosclerosis progression, platelet activation, and the development of aseptic inflammation ..." | ||
Vol 16, No 3 (2024) | Psychotic disorders in Parkinson's disease: phenomenology, pathogenesis, therapeutic approaches (modern view on the problem) | Abstract similar documents |
Kh. I. Alizade, A. A. Ragimova, E. Yu. Fedotova, S. N. Illarioshkin | ||
"... . The development and progression of psychotic symptoms in patients with PD is due to a combination of exogenous ..." | ||
Vol 8, No 4 (2016) | GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS | Abstract similar documents |
T. E. Shmidt | ||
"... of MS exacerbations and to the slower development of irreversible neurological deficit. Glatiramer ..." | ||
Vol 7, No 3 (2015) | Cognitive impairments in common and rare somatic diseases | Abstract similar documents |
Natalia Vyacheslavovna Pizova | ||
"... the progression of CIs, it is important to build a cognitive reserve in a patient; this is largely favored ..." | ||
Vol 13, No 3 (2021) | Severity and treatment of cognitive impairment | Abstract similar documents |
Yu. A. Starchina, V. V. Zakharov | ||
"... CI, which are more promising in terms of successful treatment and slowing down their progression. Age ..." | ||
Vol 11, No 1 (2019) | Molecular mechanisms of myoprotective action of chondroitin sulfate and glucosamine sulfate in sarcopenia | Abstract similar documents |
O. A. Gromova, I. Yu. Torshin, A. M. Lila, N. A. Shostak, K. V. Rudakov | ||
"... sarcopenia progression. ..." | ||
Vol 16, No 2 (2024) | Diagnosis of Alzheimer's disease by using biological markers in posterior cortical atrophy | Abstract similar documents |
D. A. Grishina, N. A. Khayalieva, V. V. Grinyuk, A. Yu. Tyurina | ||
"... impairment and mild dementia is of practical importance, as anti-amyloid therapy can prevent the progression ..." | ||
Vol 12, No 5 (2020) | Cognitive impairment, dizziness, and unsteadiness in hypertensive patients | Abstract similar documents |
L. M. Antonenko, N. V. Vakhnina, D. O. Gromova | ||
"... of vascular CI, selection of adequate therapy, and prevention of their further progression are of great ..." | ||
Vol 13, No 1 (2021) | Cognitive impairment in hypertension | Abstract similar documents |
Yu. A. Starchina, V. V. Zakharov | ||
"... the development and slowing down the progression of CI through blood pressure control. Neurometabolic ..." | ||
Vol 10, No 2 (2018) | Current management tactics for patients with dementia | Abstract similar documents |
A. V. Medvedeva, O. V. Kosivtsova, K. A. Makhinov | ||
"... Dementia develops as a result of continuous long-term progression of less severe cognitive ..." | ||
Vol 4, No 2 (2012) | Evolution of cognitive deficit: mild and moderate cognitive impairments | Abstract similar documents |
V V Zakharov | ||
"... the high risk of their progression. ..." | ||
Vol 3, No 4 (2011) | Current therapy for cognitive impairments | Abstract similar documents |
N. V. Vakhnina | ||
"... and their degree. Measures to prevent CI progression and dementia: adequate treatment of existing cardiovascular ..." | ||
Vol 17, No 1 (2025) | Lower spastic paraplegia combined with hydromyelia | Abstract similar documents |
E. G. Mendelevich, A. A. Kurbanova | ||
"... and no progression according to the MRI data. The revision of the diagnosis and the clinical and genetic analysis ..." | ||
Vol 6, No 4 (2014) | Nondrug therapy in the combination rehabilitation of patients with Parkinson’s disease | Abstract similar documents |
V. L. Golubev, A. B. Kamakinova | ||
"... wellbeing and little affects the course of the disease, without preventing its progression. Today ..." | ||
Vol 1, No 1 (2009) | THE ACUTE PERIOD OF ISCHEMIC STROKE: DIAGNOSIS AND TREATMENT | Abstract similar documents |
V. A. Parfenov | ||
"... stroke is stated to be based on the risk factors of its development, the rapid progression of focal ..." | ||
Vol 12, No 5 (2020) | Ataxia associated with anti-glutamic acid decarboxylase antibodies | Abstract PDF (Eng) similar documents |
E. P. Nuzhnyi, M. Yu. Krasnov, D. R. Akhmadullina, A. A. Abramova, E. Yu. Fedotova, S. N. Illarioshkin | ||
"... of this disease, which had a number of clinical features, such as slow progression, mild ataxia, stroke-like ..." | ||
Vol 12, No 2 (2020) | Near-moderate cognitive decline | Abstract similar documents |
N. N. Koberskaya, T. M. Ostroumova | ||
"... , when appropriate medical measures are implemented, the progression of cognitive decline can be slowed ..." | ||
Vol 11, No 3 (2019) | The use of vortioxetine for the correction of depression in Parkinson's disease: an example of clinical cases | Abstract similar documents |
I. V. Miliukhina | ||
"... is characterized by a faster progression and more significantly impaired quality of life and cognitive status than ..." | ||
Vol 8, No 3 (2016) | Epidemiology of multiple sclerosis in the Bryansk Region | Abstract similar documents |
Yu. N. Yurchenko, A. N. Yurchenko, I. V. Smagina | ||
"... and the degree of disability. The rate of MS progression was calculated from the ratio of EDSS scores at the time ..." | ||
Vol 6, No 3 (2014) | Combination treatment for acute non-specific low back pain | Abstract similar documents |
A. E. Barulin, O. V. Kurushina, A. E. Puchkov | ||
"... component, and the progression of tissue swelling. Objective: to study the efficacy of L-lysine escinate ..." | ||
Vol 14, No 1 (2022) | Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice | Abstract similar documents |
S. V. Petrov, O. V. Boyko, A. N. Boyko | ||
"... full treatment courses. HAMS diagnosis was established in the presence of two or more exacerbations per ..." | ||
Vol 10, No 1 (2018) | Post-stroke cognitive impairment (results of a 5-year follow-up) | Abstract similar documents |
S. V. Verbitskaya, V. A. Parfenov, V. A. Reshetnikov, V. V. Kozlov, A. R. Kabaeva | ||
"... follow-up has shown that post-stroke CI gradually progresses, which is associated with the progression ..." | ||
Vol 16 (2024): (Suppl. 2) | Multifactorial model of predictors of the development of depressive disorders in multiple sclerosis: a prospective longitudinal study | Abstract PDF (Eng) similar documents |
K. V. Gubskaia, Yа. V. Malygin, A. Yu. Aleksandrova | ||
"... on the development of depression were: high rate of progression of MS (Beta=0.879), highly active course of MS (Beta ..." | ||
Vol 13, No 5 (2021) | Evaluation and treatment of peripheral nervous system dysfunction in patients with prediabetes | Abstract similar documents |
O. E. Zinovyeva, T. M. Ostroumova, M. V. Koniashova, N. A. Gorbachev | ||
"... and/or progression of DN in patients with prediabetes, antioxidants are considered pathogenetic therapy. Alpha-lipoic ..." | ||
Vol 8, No 4 (2016) | GENETIC AND FUNCTIONAL FACTORS IN THE DEVELOPMENT OF COGNITIVE IMPAIRMENT IN HYPERTENSION: A PROSPECTIVE STUDY | Abstract similar documents |
Yu. V. Zhitkova, A. A. Gasparyan, D. R. Khasanova, N. R. Khasanov, V. N. Oslopov | ||
"... . The indicators CVR and NLCT may be used as predictors for the development and progression of vascular cognitive ..." | ||
Vol 10, No 1 (2018) | Possible mechanisms of cognitive dysfunction in patients with chronic forms of cerebrovascular diseases | Abstract similar documents |
O. N. Voskresenskaya, N. B. Zakharova, Yu. S. Tarasova, N. E. Tereshkina, V. A. Perepelov, E. M. Perepelova | ||
"... progression and moderate vascular CI in patients with CCI. ..." | ||
Vol 4, No 2S (2012): Сognitive and other neuropsychiatric disorders | Akatinol in the treatment of noncognitive neuropsychological disorders in neurogeriatric diseases | Abstract similar documents |
T. G. Voznesenskaya | ||
"... therapy is not performed. This may result in a rapider progression of CI and a more significant reduction ..." | ||
Vol 15 (2023): (Suppl. 1) | Prospects for the use of curcumin as an additional treatment for multiple sclerosis | Abstract similar documents |
V. S. Rogovskii, A. D. Kukushkina, A. N. Boyko | ||
"... allow slowing of disease progression and also has significant side effects, such as immunosuppressive ..." | ||
Vol 17, No 1 (2025) | Social frailty and cognitive impairment in elderly people | Abstract similar documents |
Yu. K. Komleva, A. B. Salmina, N. A. Kolotyeva, K. A. Shpiliukova, N. I. Bondar, S. N. Illarioshkin, M. A. Piradov | ||
"... the progression of CI and improve the quality of life of elderly. Our work emphasizes the need ..." | ||
1 - 70 of 161 Items | 1 2 3 > >> |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)